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Objectives: To compare the efficacy of hypnotherapy
versus gabapentin for the treatment of hot flashes in
breast cancer survivors, and to evaluate the feasibility of
conducting a clinical trial comparing a drug with a
complementary or alternative method (CAM).
Design: Prospective randomised trial.
Setting: Breast health centre of a tertiary care centre.
Participants: 15 women with a personal history of
breast cancer or an increased risk of breast cancer who
reported at least one daily hot flash.
Interventions: Gabapentin 900 mg daily in three divided
doses (control) compared with standardised
hypnotherapy. Participation lasted 8 weeks.
Outcome measures: The primary endpoints were the
number of daily hot flashes and hot flash severity score
(HFSS). The secondary endpoint was the Hot Flash
Related Daily Interference Scale (HFRDIS).
Results: 27 women were randomised and 15 (56%)
were considered evaluable for the primary endpoint (n=8
gabapentin, n=7 hypnotherapy). The median number of
daily hot flashes at enrolment was 4.5 in the gabapentin
arm and 5 in the hypnotherapy arm. HFSS scores were
7.5 in the gabapentin arm and 10 in the hypnotherapy
arm. After 8 weeks, the median number of daily hot
flashes was reduced by 33.3% in the gabapentin arm and
by 80% in the hypnotherapy arm. The median HFSS was
reduced by 33.3% in the gabapentin arm and by 85% in
the hypnotherapy arm. HFRDIS scores improved by
51.6% in the gabapentin group and by 55.2% in the
hypnotherapy group. There were no statistically
significant differences between groups.
Conclusions: Hypnotherapy and gabapentin
demonstrate efficacy in improving hot flashes.
A definitive trial evaluating traditional interventions
against CAM methods is feasible, but not without
challenges. Further studies aimed at defining evidence-
based recommendations for CAM are necessary.
Trial registration: clinicaltrials.gov (NCT00711529).
INTRODUCTION
Breast cancer is the most common cancer
among women, with more than 230 000
anticipated new cases in 2013.
1 Owing to
improvements in screening, diagnosis and
therapy for breast cancer, the survival rate
continues to improve and there are now
more than 2.5 million breast cancer survivors
in the USA.
2
Among breast cancer survivors, hot ﬂashes
are a frequent and bothersome symptom. Up
to 90% of young breast cancer survivors
experience premature menopause because of
adjuvant treatment strategies such as chemo-
therapy, antioestrogenic agents and ovarian
ablation techniques. In addition to
therapy-induced hot ﬂashes, these vasomotor
symptoms are common among breast cancer
survivors undergoing natural menopause.
3–5
Hot ﬂashes have been shown to have a sig-
niﬁcant impact on women’s mood and sleep,
and among breast cancer survivors, they are
associated with deﬁciencies in the quality of
life and survivorship.
6–8
As hot ﬂashes are caused by oestrogen
deprivation, the most effective treatment for
these vasomotor symptoms is oestrogen
replacement therapy. However, despite a lack
of data demonstrating an increased risk of
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This is the first investigation comparing hypno-
therapy to a standard-of-care treatment for hot
flashes in breast cancer survivors. Our results
add to the accumulating body of evidence sup-
porting the use of CAM for symptom manage-
ment in cancer survivors.
▪ This pilot study could not demonstrate statistical
differences between the two treatment groups
because of the small numbers. Nonetheless, the
findings are clinically relevant. Our experience
elucidated potential barriers in the design and
implementation of phase III trials evaluating CAM
against current standards of care.
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Open Access Researchdeveloping primary or recurrent breast cancer from oes-
trogen replacement alone, its use in breast cancer survi-
vors or women at risk for developing breast cancer is
largely considered a contraindication.
9 Even among
women whose medical oncologists feel comfortable pre-
scribing oestrogen replacement, less than a third are
willing to try it.
10
Non-hormonal drug therapies for the treatment of hot
ﬂashes have demonstrated moderate efﬁcacy but are asso-
ciated with side effects. The most commonly prescribed
agents are antidepressants, which have been shown to
reduce self-reported hot ﬂashes in breast cancer survivors
by up to 61%.
11–18 However, antidepressants may interfere
with the metabolism of tamoxifen, a common treatment
for oestrogen receptor-positive breast cancers, by inhibit-
ing the CYP2D6 enzyme.
19 Venlafaxine is the most com-
monly prescribed antidepressant for hot ﬂashes and has
only minimal inhibition of cyp2D6 without known clinical
signiﬁcance. However, gabapentin, a γ-amino-butyric acid
analogue commonly used for the treatment of seizure dis-
orders and neuropathic pain, has no effect on cyp2D6
metabolism.
20
The efﬁcacy of gabapentin to manage hot ﬂashes was
demonstrated in women undergoing natural menopause,
showing comparable results as oestrogen replacement.
21
In a randomised trial against a placebo, hot ﬂashes were
decreased by 51% in those treated with gabapentin, com-
pared with 26% in those treated with placebo (p<0.001).
While dizziness, unsteadiness and drowsiness were
reported in the ﬁrst week among women taking gabapen-
tin, symptoms resolved within 4 weeks.
22
Gabapentin was further validated as a treatment for
hot ﬂashes in breast cancer survivors, including women
already taking an antidepressant.
23–25 In a deﬁnitive
study of 420 women who were randomised to receive
gabapentin 300 mg/day, gabapentin 900 mg/day or
placebo, the 900 mg/day dose of gabapentin was the
most effective, decreasing the frequency of hot ﬂashes
by 41% at 4 weeks compared with 17% reduction in the
placebo group. However, in this same treatment group,
there was a 12% withdrawal rate at 4 weeks, and 17% at
8 weeks, owing to side effects and subjective inefﬁcacy.
24
The need for non-pharmaceutical treatment options
for hot ﬂashes in cancer survivors is evident by the high
dropout rates seen in these drug studies. Limited
options for safe and effective non-hormonal drugs and
increasing interest among women in complementary
and alternative medicine (CAM) have led to the need
for investigation of non-pharmacological modalities.
Hypnosis is a mind–body therapy involving the induc-
tion of a state of deep relaxation that allows the patient
to suspend critical faculties and allow suggestibility. In a
pilot study evaluating hypnotherapy for the treatment of
hot ﬂashes in breast cancer survivors, 16 women experi-
enced a 59% reduction in hot ﬂash frequency.
26 In a
randomised trial comparing hypnotherapy to no treat-
ment, 60 female breast cancer survivors were rando-
mised to receive either hypnosis or no treatment. The
women who underwent hypnotherapy reported a reduc-
tion in hot ﬂash severity scores (HFSS) of 68%, and also
reported improvement in quality of life variables such as
insomnia.
27 Women receiving hypnotherapy did not
report side effects in either trial.
Hypnotherapy has been further validated as a treatment
of hot ﬂashes in a recent clinical trial that randomised 187
postmenopausal women to undergo clinical hypnosis or
structured-attention control.
28 Women in the treatment
group experienced a 74% reduction in hot ﬂash frequency
compared with a 17% reduction in the control group.
These authors devised a structured-attention exposure to
therapists to serve as a placebo-like control. However, clin-
ical trials evaluating CAM modalities are often limited by
inadequate control groups, and hypnotherapy has never
been compared directly to a standard therapy in the treat-
ment of hot ﬂashes.
To address the needs of the growing population of
breast cancer survivors, we designed this study to assess the
feasibility of a prospective randomised controlled trial
evaluating the efﬁcacy of hypnotherapy versus gabapentin
for the treatment of hot ﬂashes in women with a personal
history or increased risk of developing breast cancer.
PATIENTS AND METHODS
Women were enrolled and monitored in the breast
health centre of a tertiary care centre (Women and
Infants Hospital, Providence, Rhode Island, USA).
Eligible patients were at least 18 years of age and had
a history of breast cancer without evidence of current
disease. To improve accrual, eligibility was expanded to
include women who had an increased risk of developing
breast cancer in their lifetime. ‘Increased risk’ was
deﬁned as age greater than 60, BRCA mutation or
strong family history, history of preinvasive breast lesion
or a lifetime Gail model score of 1.6% or greater.
Women taking antioestrogen therapy such as tamoxifen
or aromatase inhibitors were included. Eligible women
reported at least one daily hot ﬂash. Women with persist-
ent daily hot ﬂashes undergoing other treatments, such
as medications or counselling, were included as long as
they were not taking gabapentin or undergoing hypno-
therapy. All participants were asked not to initiate new
therapy for hot ﬂashes during the study period.
Women were excluded who were undergoing chemo-
therapy or radiation for their breast cancer, or who had
serious psychiatric or medical illness that may interfere
with participation in the protocol. All patients provided
written informed consent.
Participants were randomised to receive gabapentin in
the control arm or standardised hypnotherapy in the
experimental arm based on a block randomisation
scheme generated at http://www.randomization.com.
Participation lasted 8 weeks in both arms.
Women assigned to the control arm were prescribed
gabapentin 900 mg daily by the principal investigator, in
three divided doses.
24 Patients randomised to the
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inductions by a single certiﬁed hypnotherapist, each
1 week apart. Standardised outlines were used for each
induction. The ﬁrst session consisted of an induction
directed towards complete relaxation and suggesting
that the woman can control her symptoms with her
unconscious mind. The second and third sessions also
began with a standardised induction, followed by the
establishment of an ‘anchor’, or physical reference point
(foreﬁnger to thumb), used to invoke images of cool-
ness, which were individualised according to patient
preference. Patients were also instructed by the same
hypnotherapist in self-hypnosis and guided imagery
techniques to be used at home with the assistance of
standardised audio CDs.
Women were asked to keep a daily hot ﬂash diary for
the 8 weeks of participation.
29 Quality of life data were
collected with the Hot Flash Related Daily Interference
Scale (HFRDIS)
30 conducted on the day of enrolment,
and at 4-week and 8-week follow-up visits.
The primary endpoints for this study were daily fre-
quency of hot ﬂashes and HFSS, both of which were
derived from participants’ diaries. HFSS were calculated by
assigning one point to each mild hot ﬂash, two points for
each moderate hot ﬂash, three points for each severe hot
ﬂash and four points for each very severe hot ﬂash. The
secondary endpoint was HFRDIS scores. A modiﬁed
intention-to-treat analysis was performed, including all data
provided by the participants randomised. Fisher’se x a c tt e s t
was used to compare categorical variables and the
Wilcoxon rank-sum test/Mann-Whitney U test was used to
compare continuous variables using the SAS V.9.2 statistical
package (SAS Institute, Cary, North Carolina, USA).
A power analysis was conducted to determine the
sample size needed for a deﬁnitive study. Based on an
80% power to detect a doubling of effect in the experi-
mental arm compared with control (with α=0.05), a
sample size of 64 women in each arm would be neces-
sary. In this pilot feasibility study, we set a goal of recruit-
ing 60 women into participation. We concluded
enrolment after a predetermined 2-year time period.
RESULTS
Between September 2008 and September 2010, 73 women
were screened for this study. Fourteen women were
deemed ineligible and 32 decided not to participate. A
total of 27 women were randomised to receive treatment,
14 to gabapentin and 13 to hypnotherapy (ﬁgure 1). Two
women randomised to receive hypnotherapy were disquali-
ﬁed: one did not speak English and could therefore not
comply with the hypnotherapy protocol, and the other
had active metastatic disease. A total of ﬁve patients
dropped out prior to initiating treatment. Three did not
want to take gabapentin, and two could not ﬁth y p n o t h e r -
apy sessions into their work schedules.
Eleven patients initiated gabapentin therapy, and eight
completed the study. The three women who discontinued
the drug cited side effects and inefﬁcacy as their reasons.
These three women declined further participation in the
study and did not submit their hot ﬂash diaries.
Nine patients initiated hypnotherapy. One patient
underwent two of three inductions; otherwise, all nine
completed the study protocol. All nine were included in
the analysis; however, two women in the hypnotherapy
arm were not evaluable for the primary endpoint
because of lost hot ﬂash diaries.
Demographic data of the two groups are presented in
table 1. There were no signiﬁcant differences between
the groups.
Hot ﬂash frequencies and HFSS were derived from
the submitted diaries. Data were available for eight
women in the gabapentin arm and seven women in the
hypnotherapy arm. The median number of daily hot
ﬂashes at enrolment was 4.5 in the gabapentin arm and
5 in the hypnotherapy arm (table 2A). After 8 weeks,
the median number of daily hot ﬂashes was reduced by
33.3% in the gabapentin arm and by 80% in the hypno-
therapy arm (ﬁgure 2). The median HFSS at baseline
was 7.5 in the gabapentin arm (n=8) and 10 in the
hypnotherapy arm (n=7; table 2B). The median HFSS
was reduced by 33.3% in the gabapentin arm and by
85% in the hypnotherapy arm (ﬁgure 3). These do not
represent statistically signiﬁcant differences between
treatment arms.
Baseline HFRDIS data were available for all women
who initiated therapy, and scores for the two treatment
groups were similar (table 2C). There was no difference
in treatment effect between the two groups. Overall, the
HFRDIS scores improved by 51.6% in the gabapentin
group and by 55.2% in the hypnotherapy group.
Sensitivity analyses were performed for all endpoints,
imputing values for non-responders that assumed
greater and lesser improvement. Observed differences
in treatment effects still did not reach statistical
signiﬁcance.
DISCUSSION
The ﬁndings of our study suggest the efﬁcacy of hypno-
therapy and gabapentin with a noteworthy trend towards
a beneﬁt for hypnosis. While not statistically signiﬁcant,
we believe that these results are clinically important and
warrant further investigation.
None of the women in the hypnotherapy arm
reported adverse effects of their treatment, and all
women reported that they felt the hypnosis worked.
However, two women were never able to undergo hypno-
therapy because of scheduling conﬂicts, and a third
woman only had two of three planned sessions for the
same reason. Conversely, three women in the gabapen-
tin arm dropped out after randomisation and before
starting the drug, and three dropped out due to side
effects (worsening vertigo and fatigue) and inefﬁcacy.
This is consistent with the anticipated dropout rate
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treatment of hot ﬂashes.
21 22 24
In women undergoing hypnotherapy, we report an
80% improvement in hot ﬂash frequency and an 85%
improvement in HFSS. This treatment effect is similar to
that in previous studies evaluating hypnotherapy, and
apparently stronger than what has been reported previ-
ously for gabapentin.
21–28 However, caution is necessary
in comparing results across studies. For example,
Elkins’s most recent clinical trial among postmenopausal
women required a minimum of seven daily hot ﬂashes.
That study was able to demonstrate a 74% reduction in
hot ﬂashes compared with 17% in the control group. In
contrast, in the deﬁnitive study demonstrating the efﬁ-
cacy of gabapentin, women were included who had at
least two daily hot ﬂashes and demonstrated a 44%
reduction in hot ﬂash frequency over 8 weeks (com-
pared with 15% in control).
24 In a population with
more frequent and more severe hot ﬂashes, a treatment
effect is easier to demonstrate, and this must be taken
into account when examining eligibility criteria and
comparing the results of one trial with that of another.
A direct comparison in a deﬁnitive trial is necessary to
determine superiority because of the signiﬁcant
Figure 1 Consort flow diagram for screening and enrolment. *Two patients lost their hot flash diaries and therefore were not
evaluable for the primary endpoint.
Table 1 Demographic data of participants
Gabapentin Hypnotherapy p Value*
n=14 n=11
Median age 52 (45, 63) 56 (42, 62) –
Race
Caucasian 14 (100%) 10 (90.9%) 0.4
African-American 0 1 (9.1%)
History of cancer 11 (78.6%) 5 (45.5%) 0.1
Tamoxifen 6 (42.9%) 3 (27.3%) 0.7
Antidepressant use 3 (21.4%) 2 (18.2%) 1.0
Baseline daily hot flashes
1–5 3 (21.4%) 1 (9.1%) 0.8
5–10 8 (57.1%) 8 (72.7%)
>10 3 (21.4%) 2 (18.2%)
*Fisher’s exact test.
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populations studied.
Women are frequent users of CAM therapies and have
reported using such modalities for menopausal symp-
toms. A survey of 886 women aged 45–65 years reported
that 76.1% were using some kind of CAM therapy and
22.1% were using it speciﬁcally for menopausal symp-
toms.
31 More than half of the breast cancer survivors
reported using CAM in the Nurses’ Health Study.
32 In
the light of the increasing interest in CAM therapies
among women and cancer survivors and the National
Cancer Institute’s Initiative to expand the goal of clinical
trials to address symptom management in cancer care, a
need has arisen for clinical trials evaluating CAM modal-
ities for the treatment of cancer and treatment-related
symptoms. In the study presented here, we explored the
feasibility of comparing the efﬁcacy of a CAM modality
in a prospective randomised clinical trial with a standard
pharmacological therapy as a control for the treatment
of hot ﬂashes.
Table 2 Comparison of primary and secondary endpoints
A. Hot flash frequencies
Number of daily hot flashes
p Value*
Hypnotherapy (n=7) Gabapentin (n=8)
Median (range); n Median (range); n
Baseline 5.0 (2, 11); 7 4.5 (2, 9); 8 1.0
Week 4 4.0 (1, 7); 6 4.0 (2, 9); 7 0.7
Week 8 1.0 (0, 7); 6 3.0 (3, 5.5); 5 0.3
Percentage of decrease† 80% 33.3%
B. Hot flash severity scores (HFSSs)
HFSS
Hypnotherapy (n=7) Gabapentin (n=8)
Median (range); n Median (range); n p Value*
Baseline 10.0 (2.0, 14.0); 7 7.5 (2.0, 19.0); 8 0.7
Week 4 6.5 (1.0, 11.0); 6 4.0 (2.0, 17.5); 7 0.6
Week 8 1.5 (0, 12.0); 6 5.0 (3.0, 11.5); 5 0.3
Percentage of decrease 85% 33.3%
C. Hot Flash Related Daily Interference Scale (HFRDIS) scores
HFRDIS
Hypnotherapy (n=11) Gabapentin (n=14)
Median (range); n Median (range); n p Value*
Baseline 58.0 (16, 64); 11 45.5 (11, 82); 14 0.8
Week 4 25.5 (1, 57); 6 12.5 (0, 57); 8 0.8
Week 8 26.0 (0, 68); 9 22.0 (7, 41); 7 0.9
Percentage of decrease 55.2% 51.6%
*Wilcoxon rank-sum test/Mann-Whitney U test.
†Percentage decrease over 8-week treatment period was calculated as (baseline median−week 8 median)/baseline median.
Figure 3 Median hot flash severity scores. Figure 2 Median number of daily hot flashes.
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trial, but several points are worthy of discussion regard-
ing the study design.
As i g n i ﬁcant deﬁcit of trials investigating CAM therapies
is the lack of an adequate control group.
33 For example,
there is no ‘placebo’ equivalent to therapies such as
hypnotherapy, and patients and providers cannot be
blinded to whether patients are undergoing hypnosis.
Elkins et al accounted for this in their study evaluating
breast cancer survivors by controlling their randomised
trial with a group of women who were placed on a waiting
list for hypnotherapy. The women in the control arm
experienced no signiﬁcant change in their hot ﬂashes,
consistent with a ‘no treatment’ intervention.
27 However,
in the case of hot ﬂashes, there is a well-established
placebo effect of 20–30% observed in clinical trials evaluat-
ing medications, suggesting that ‘no treatment’ arms may
not be adequate controls either.
29 In their more recent
trial evaluating hypnotherapy for hot ﬂashes in postmeno-
pausal women, Elkins et al
28 used a structured-attention
control designed to mimic the hypnotherapy intervention
without therapeutic intent. This allowed for a single-
blinded model, and the ‘placebo’ effect was 17%, similar
to that seen in the control arm of the drug trials.
It is difﬁcult to control for a provider bias with a
single-blinded study, and comparing treatment effect
results between trials is an unreliable method as dis-
cussed. Therefore, we advocate comparing hypnosis dir-
ectly with an evidence-based standard therapy in a
deﬁnitive study. However, we encountered signiﬁcant
obstacles to accrual with such a study design.
In our 2 years of recruitment, we were able to formally
screen only 73 women. We hypothesise the low rate of
referral to be secondary to a deﬁcit in knowledge
regarding CAM among referring physicians. In a separ-
ate study, we queried healthcare providers who care for
breast cancer survivors regularly. Every provider reported
a willingness to refer patients to a clinical trial involving
CAM, but only 25% felt qualiﬁed to counsel a patient
regarding CAM modalities (Malit et al, NEAGO 2010).
In addition, among the women screened, the majority
was deemed eligible (n=59), but less than half were
willing to undergo randomisation because of a strong
preference to avoid taking a medication. Among the 14
women randomised to the gabapentin arm, only 8 com-
pleted treatment. Our experience suggests an inherent
bias among women regarding their treatment options.
This was conﬁrmed in a survey of breast health patients
in which 67% reported their willingness to participate in
a clinical trial evaluating a CAM modality, and only 48%
would agree to a trial in which a medication was the
control (Malit et al, NEAGO 2010). The majority of
these women reported that their cancer-related symp-
toms were not severe enough to undergo any treatment,
emphasising the need to distinguish daily hot ﬂashes
from bothersome hot ﬂashes.
Limited accrual necessitates broad eligibility criteria in
study design. We included any woman with a personal
history of breast cancer or an increased risk of developing
breast cancer over her lifetime. Though the objective of
our research was to address cancer-related symptoms, the
issue of therapy-induced hot ﬂashes is also relevant for
women taking the prophylactic tamoxifen. Bothersome
hot ﬂashes, whether treatment related or not, are a
common problem among all women, and a larger clinical
trial would allow for detection of potential differences in
effect among breast cancer survivors and other women.
In addition, it is common practice for investigators to
include all women with a ‘real or perceived risk’ of breast
cancer related to oestrogen replacement in clinical trials
investigating hot ﬂash therapies.
16 22 27 29
Also in an effort to maximise accrual, we chose to
include women who reported at least one daily hot ﬂash.
This is a lower threshold of hot ﬂash frequency required
for enrolment than other studies, resulting in lower base-
line daily hot ﬂash frequencies of 4.5 in the gabapentin
arm and 5 in the hypnotherapy arm.
11 22–27 The lower
baseline frequency may explain why the treatment effect
in the gabapentin arm was only 33.3%, lower than previ-
ous studies and more consistent with that in the placebo
arm in most clinical trials evaluating hot ﬂashes.
23–25 29
Our study also included women who were already on
therapies for their hot ﬂashes or medications that could
affect their hot ﬂashes, such as antidepressants. These
treatments could be considered as confounding vari-
ables in determining the treatment effect of our study
interventions. However, these women still had to meet
the eligibility criterion of one daily hot ﬂash and were
asked to avoid making changes in their therapies during
the study period. This allowed for evaluation of our
treatment modalities among women who were suffering
persistent hot ﬂashes despite other therapies, an
approach supported by previous studies.
25
Sufﬁcient data exist for the use of either gabapentin
or hypnotherapy for the treatment of hot ﬂashes in
women who cannot or will not take oestrogen replace-
ment for the treatment of hot ﬂashes. However, a larger
deﬁnitive trial is justiﬁed despite the challenges for a
number of reasons. Further research evaluating CAM
compared with standard therapies will provide evidence
needed by many providers to make referrals, a safer
approach than patients referring themselves for hypno-
sis. Further education in CAM modalities among physi-
cians would improve accrual and recruitment into
clinical trials. A larger study would also provide the
opportunity to investigate whether there are predictive
variables for the efﬁcacy of each modality or speciﬁc
effects on quality of life variables, which would allow for
long-term follow-up evaluations, and which are lacking
in the current literature on hot ﬂash therapies.
The use of hormone replacement and the associated
risk of recurrent or new breast cancer is controversial.
However, a growing numberof women are either unwilling
or unable to take oestrogen replacement therapy for treat-
ment of their vasomotor symptoms, and many are not
interested in taking medications. Hypnotherapy is a CAM
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Open Accessmodality with no known adverse effects; it is a promising,
safe and effective alternative to pharmacological therapies
for hot ﬂashes. Further studies evaluating hypnotherapy
compared with standard therapies are needed.
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